Julianna Lisziewicz PhD

For more than 25 years, Dr. Lisziewicz has built and directed research teams that develop immunotherapy products that enable the human immune systems to conquer some of the most deadly diseases, including HIV and cancer. Prior to founding Treos, Dr. Lisziewicz founded and directed research and biologic drug development at two companies as the President, CEO, and Founder of Genetic Immunity, Inc., and as the Director and Founder of the non-profit Research Institute for Genetic and Human Therapy (RIGHT).
She discovered and led the preclinical and clinical development of DermaVir HIV immunotherapy through a successful Phase 2 clinical trial. Earlier, she pioneered gene therapy for HIV/AIDS treatment at the National Cancer Institute. Dr. Lisziewicz is a graduate of Budapest Technical University, Budapest, Hungary (BS and MSc) and Braunschweig Technical University and Max-Planck Institute, Germany (PhD).